

Emilie Le Rhun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6897111/publications.pdf>

Version: 2024-02-01

158
papers

9,970
citations

61984

43
h-index

42399

92
g-index

182
all docs

182
docs citations

182
times ranked

10195
citing authors

#	ARTICLE	IF	CITATIONS
1	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
2	Ethanol Exposure During the Intravenous Administration of Chemotherapeutic Drugs: An Analysis of Clinical Practice and a Literature Review. <i>JCO Oncology Practice</i> , 2022, , OP2100430.	2.9	2
3	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	1.2	38
4	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
5	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	1.2	13
6	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	7.7	18
7	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	30.7	30
8	Venous thromboembolic events in glioblastoma patients: An epidemiological study. <i>European Journal of Neurology</i> , 2022, 29, 2386-2397.	3.3	7
9	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2055-2055.	1.6	0
10	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2026-2026.	1.6	0
11	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
12	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	1.2	42
13	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	27.6	826
14	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.6	9
15	Leptomeningeal metastases from solid tumours. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 192-197.	0.5	2
16	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	1.6	3
17	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	7.7	34
18	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021, 23, 1835-1844.	1.2	64

#	ARTICLE	IF	CITATIONS
19	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2021, 32, 1332-1347.	1.2	227
20	SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , 2021, 3, iii25-iii25.	0.7	0
21	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	2.8	16
22	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1821-1834.	1.2	230
23	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	1.2	59
24	Leptomeningeal Disease. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 189-215.	2.2	1
25	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi127.	1.2	1
26	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. <i>Neuro-Oncology</i> , 2020, 22, 524-538.	1.2	63
27	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMOâ€“EONSâ€“EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1306-1319.	1.2	146
28	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	7.0	102
29	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020, 5, e000763.	4.5	20
30	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.6	19
31	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , 2020, 13, 100852.	3.7	4
32	Antidepressant drug use in glioblastoma patients: an epidemiological view. <i>Neuro-Oncology Practice</i> , 2020, 7, 514-521.	1.6	4
33	DEPOSEINâ€“how meaningful was the benefit from intrathecal chemotherapy?. <i>Neuro-Oncology</i> , 2020, 22, 1710-1711.	1.2	0
34	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. <i>Cancers</i> , 2020, 12, 3775.	3.7	9
35	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39
36	How did lomustine become standard of care in recurrent glioblastoma?. <i>Cancer Treatment Reviews</i> , 2020, 87, 102029.	7.7	119

#	ARTICLE	IF	CITATIONS
37	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
38	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020, 480, 24-28.	7.2	33
39	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
40	Interferon γ sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Oncology Letters</i> , 2020, 19, 2649-2656.	1.8	6
41	Treatment of Leptomeningeal Metastases. , 2020, , 301-311.		0
42	Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors. , 2020, , 173-179.		0
43	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14530-e14530.	1.6	0
44	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2532-2532.	1.6	0
45	Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. <i>ESMO Open</i> , 2020, 5, e001034.	4.5	13
46	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1400-1407.	1.1	23
47	How we treat glioblastoma. <i>ESMO Open</i> , 2019, 4, e000520.	4.5	62
48	Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , 2019, 145, 487-499.	2.9	8
49	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019, 80, 101896.	7.7	386
50	OS8.6 Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Neuro-Oncology</i> , 2019, 21, iii17-iii17.	1.2	0
51	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 339-347.	2.9	7
52	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. <i>Neurology</i> , 2019, 93, e1799-e1806.	1.1	17
53	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	1.2	114
54	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma—a randomised multicentre trial (ASTER trial). An ANOCEF study. <i>European Journal of Cancer</i> , 2019, 109, 129-136.	2.8	13

#	ARTICLE	IF	CITATIONS
55	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019, 21, 648-658.	1.2	90
56	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.1	9
57	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019, 4, e000507.	4.5	79
58	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. <i>Neuro-Oncology</i> , 2019, 21, vi76-vi76.	1.2	0
59	DDIS-04. INTERFERON- γ SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02. <i>Neuro-Oncology</i> , 2019, 21, vi65-vi66.	1.2	0
60	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. <i>Annals of Oncology</i> , 2019, 30, 211-218.	1.2	96
61	Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. <i>International Journal of Cancer</i> , 2019, 145, 242-253.	5.1	27
62	A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1017-1017.	1.6	31
63	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007.	1.6	13
64	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2056-2056.	1.6	3
65	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2072-TPS2072.	1.6	6
66	Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13546-e13546.	1.6	0
67	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	10.7	32
68	The Evolving Landscape of Brain Metastasis. <i>Trends in Cancer</i> , 2018, 4, 176-196.	7.4	194
69	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	2.8	17
70	Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. <i>European Journal of Cancer</i> , 2018, 95, 75-84.	2.8	72
71	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	2.0	94
72	Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1213-1216.e2.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Neurological Complications of Breast Cancer and Its Treatment. , 2018, , 435-469.		0
74	Leptomeningeal Metastasis as Complication of Systemic Cancers. , 2018, , 81-111.		0
75	Farewell to monomodality treatment in patients with WHO lower grade glioma?. European Journal of Cancer, 2018, 88, 109-114.	2.8	1
76	Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial. Annals of Oncology, 2018, 29, viii122.	1.2	6
77	P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, iii238-iii238.	1.2	0
78	P01.034 Prospective evaluation of alternative therapies in glioma patients in France. Neuro-Oncology, 2018, 20, iii236-iii236.	1.2	0
79	P04.11 Profound sensitivity of glioblastoma cells to apoptosis induction by TG02, a novel oral multi-cyclin-dependent kinase inhibitor. Neuro-Oncology, 2018, 20, iii280-iii280.	1.2	0
80	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. European Journal of Cancer, 2018, 101, 95-104.	2.8	11
81	Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. Journal of Clinical Oncology, 2018, 36, 9520-9520.	1.6	3
82	Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, 2042-2042.	1.6	0
83	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, e14070-e14070.	1.6	1
84	Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology, 2017, 19, now183.	1.2	157
85	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treatment Reviews, 2017, 53, 128-137.	7.7	146
86	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	1.2	381
87	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
88	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. Journal of Neuro-Oncology, 2017, 133, 419-427.	2.9	52
89	Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 875-890.	2.3	36
90	Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. Cancer Control, 2017, 24, 22-32.	1.8	20

#	ARTICLE	IF	CITATIONS
91	Evidence-based management of adult patients with diffuse glioma – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431.	10.7	5
92	Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. <i>Annals of Oncology</i> , 2017, 28, 2962-2976.	1.2	57
93	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	27.0	670
94	Chemical meningitis related to intra-CSF liposomal cytarabine. <i>CNS Oncology</i> , 2017, 6, 261-267.	3.0	7
95	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	2.8	34
96	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology</i> , The, 2017, 18, e330-e340.	10.7	195
97	EANO – ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. <i>Annals of Oncology</i> , 2017, 28, iv84-iv99.	1.2	331
98	Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. <i>Journal of Cancer</i> , 2017, 8, 1417-1424.	2.5	8
99	Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2007-2007.	1.6	0
100	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2076-2076.	1.6	0
101	Prognosis of leptomeningeal metastases from melanoma: A case series of 28 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13550-e13550.	1.6	3
102	Vascular complications in glioma patients. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 251-266.	1.8	8
103	ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS. <i>Neuro-Oncology</i> , 2016, 18, vi8-vi8.	1.2	2
104	BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. <i>Neuro-Oncology</i> , 2016, 18, vi30-vi30.	1.2	1
105	Leptomeningeal metastases of solid cancer. <i>Current Opinion in Neurology</i> , 2016, 29, 797-805.	3.6	39
106	Radionecrosis after stereotactic radiotherapy for brain metastases. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 903-914.	2.8	73
107	Systemic therapy for recurrent meningioma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 889-901.	2.8	20
108	Chemotherapy-Related Neurotoxicity. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 81.	4.2	77

#	ARTICLE	IF	CITATIONS
109	Essentials for clinicians: head and neck tumours and neuro-oncology. ESMO Open, 2016, 1, e000156.	4.5	0
110	Neoplastic Meningitis. , 2016, , 63-77.		1
111	Neuroradiology of Leptomeningeal Metastases. , 2016, , 705-721.		1
112	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. Current Neurology and Neuroscience Reports, 2016, 16, 15.	4.2	23
113	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 2016, 18, 401-407.	1.2	53
114	Venous thrombosis in patients with high-grade glioma. Current Opinion in Oncology, 2015, 27, 516-521.	2.4	14
115	Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. Melanoma Research, 2015, 25, 302-305.	1.2	53
116	Radiation-associated grade 2 meningiomas: A nine patient-series and review of the literature. Clinical Neurology and Neurosurgery, 2015, 136, 10-14.	1.4	5
117	Immunotherapy with CpGâ€œODNâ€œ in neoplastic meningitis: A phase I trial. Cancer Science, 2015, 106, 1212-1218.	3.9	24
118	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncology, 2015, 4, 381-386.	3.0	18
119	Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. Case Reports in Oncology, 2015, 8, 72-77.	0.7	10
120	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
121	Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics, 2015, 15, 601-620.	2.8	21
122	CellSearchÂ® technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. Lung Cancer, 2015, 90, 352-357.	2.0	42
123	Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. Journal of Neuro-Oncology, 2015, 124, 317-323.	2.9	31
124	A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormone therapy. Breast Cancer Research and Treatment, 2015, 152, 569-580.	2.5	32
125	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	10.7	108
126	Neurosurgical and radiosurgical decision making in brain metastasis patients in the area of targeted therapies?. Chinese Clinical Oncology, 2015, 4, 19.	1.2	8

#	ARTICLE	IF	CITATIONS
127	Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8138-8152.	4.1	4
128	Surgery followed by radiosurgery: A deliberate valuable strategy in the treatment of intracranial meningioma. <i>Clinical Neurology and Neurosurgery</i> , 2014, 124, 123-126.	1.4	14
129	BM-18 * PROLONGED RESPONSE WITH BEVACIZUMAB + NAVELBINE AS THIRD LINE OF TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASES: A CASE REPORT. <i>Neuro-Oncology</i> , 2014, 16, v36-v36.	1.2	1
130	CSF CA 15-3 in breast cancer-related leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2014, 117, 117-124.	2.9	17
131	Cerebral amyloid angiopathy revealed by rapidly progressing leptomeningeal lesions. <i>Journal of Neurology</i> , 2014, 261, 1432-1435.	3.6	1
132	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2014, 25, 2351-2356.	1.2	51
133	Intracranial Cystic Lesions: A Review. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 481.	4.2	40
134	Relevance of gamma knife radiosurgery alone for the treatment of non-small cell lung cancer brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 87-93.	1.4	7
135	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014, 16, 1176-1185.	1.2	141
136	Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine. <i>Case Reports in Oncology</i> , 2014, 7, 555-559.	0.7	2
137	A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. <i>Journal of Neuro-Oncology</i> , 2013, 113, 83-92.	2.9	97
138	Detection and quantification of CSF malignant cells by the CellSearch® technology in patients with melanoma leptomeningeal metastasis. <i>Medical Oncology</i> , 2013, 30, 538.	2.5	55
139	Memory loss during lenalidomide treatment: a report on two cases. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 41.	2.4	19
140	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 64-71.	10.7	622
141	Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases. <i>Anti-Cancer Drugs</i> , 2013, 24, 1093-1097.	1.4	9
142	Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. , 2013, 4, 265.		245
143	Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study. <i>BMC Health Services Research</i> , 2013, 13, 456.	2.2	5
144	Intradural Extramedullary Spinal Metastases of Non-neurogenic Origin. <i>Neurosurgery</i> , 2013, 73, 923-932.	1.1	24

#	ARTICLE	IF	CITATIONS
145	Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocéf phase II trial.. Journal of Clinical Oncology, 2013, 31, 2020-2020.	1.6	12
146	Cotard's syndrome with glioblastoma multiforme. Palliative and Supportive Care, 2012, 10, 135-139.	1.0	12
147	Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clinical Pathology, 2012, 12, 21.	1.8	53
148	Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. Bulletin Du Cancer, 2012, 99, E75-E80.	1.6	5
149	Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. Journal of Neuro-Oncology, 2012, 109, 167-175.	2.9	51
150	Supportive care in neurooncology. Revue Neurologique, 2011, 167, 762-772.	1.5	5
151	Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. American Journal of Human Genetics, 2011, 89, 398-406.	6.2	250
152	Complications related to the placement of an intraventricular chemotherapy device. Journal of Neuro-Oncology, 2011, 104, 247-252.	2.9	8
153	Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. Journal of Neuro-Oncology, 2011, 105, 309-315.	2.9	25
154	SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Human Mutation, 2011, 32, E2079-90.	2.5	34
155	Securing the circuit of intrathecally administered cancer drugs: example of a collective approach. Journal of Oncology Pharmacy Practice, 2011, 17, 252-259.	0.9	4
156	Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures. Breast Cancer Research and Treatment, 2010, 121, 23-33.	2.5	15
157	Different patterns of Mini Mental Status Examination responses in primary progressive aphasia and Alzheimer's disease. European Journal of Neurology, 2006, 13, 1124-1127.	3.3	10
158	Natural history of primary progressive aphasia. Neurology, 2005, 65, 887-891.	1.1	108